The 146th Annual Meeting of the Pharmaceutical Society of Japan (Osaka)
Advanced Search

Session Details

Symposium

[S18★☆]Recent trends and future perspectives for non-clinical pharmacokinetics and safety evaluation of therapeutic monoclonal antibodies —at the dawn of a new era

Fri. Mar 27, 2026 1:10 PM - 3:10 PM JST
Fri. Mar 27, 2026 4:10 AM - 6:10 AM UTC
Room 20 (D302)
Organizer: Akiko Ishii-Watabe (National Inst. Health Sciences), Mutsumi Suzuki (JPMA/Kyowa Kirin)
1:10 PM - 1:13 PM JST(4:10 AM - 4:13 AM UTC)

抗体医薬品の非臨床薬物動態・安全性評価に関する最新動向と展望：趣旨説明
石井 明子（国立衛研）

1:13 PM - 1:36 PM JST(4:13 AM - 4:36 AM UTC)

[S18-1]Global trends in nonclinical safety assessment and perspectives for utilizing new approach methods (NAMs) in antibody drug evaluation

○Yoko Hirabayashi1 (1. National Institute of Health Sciences)
1:36 PM - 1:59 PM JST(4:36 AM - 4:59 AM UTC)

[S18-2]A human spheroidal blood brain-barrier model for translational evaluation of brain-penetrating antibodies

○Tomomi Furihata1 (1. Sch. Pharm., Tokyo Univ. Pharm. & Life Sci.)
1:59 PM - 2:22 PM JST(4:59 AM - 5:22 AM UTC)

[S18-3]Preclinical DMPK research on next-generation engineered antibodies

○Kenta Haraya1 (1. Discovery Biologics Department, Research Division, Chugai Pharmaceutical Co., Ltd.)
2:22 PM - 2:45 PM JST(5:22 AM - 5:45 AM UTC)

[S18-4]In vitro assay for evaluating target antigen-independent cytotoxicity of antibody-drug conjugates

○Michihiko Aoyama1 (1. National Institute of Health Sciences)
2:45 PM - 3:10 PM JST(5:45 AM - 6:10 AM UTC)

[S18-5]The Current Status of Nonclinical Safety Evaluation of Antibody Therapeutics

○Mutsumi Suzuki1,2 (1. Non-Clinical Evaluation Expert Committee, Drug Evaluation Committee, JPMA, 2. TR Labs, Kyowa Kirin)
Back to Category List